The efficacy and safety of sertraline in maintenance hemodialysis patients with depression: A randomized controlled study

作者全名："Zhang, Shunjuan; Xu, Ya; Xia, Yunfeng"

作者地址："[Zhang, Shunjuan; Xu, Ya; Xia, Yunfeng] Chongqing Med Univ, Dept Nephrol, Affiliated Hosp 1, 1 Youyi Rd,Yuanjiagang, Chongqing 400016, Peoples R China"

通信作者："Xia, YF (通讯作者)，Chongqing Med Univ, Dept Nephrol, Affiliated Hosp 1, 1 Youyi Rd,Yuanjiagang, Chongqing 400016, Peoples R China."

来源：JOURNAL OF AFFECTIVE DISORDERS

ESI学科分类：PSYCHIATRY/PSYCHOLOGY

WOS号：WOS:001188070600001

JCR分区：Q1

影响因子：6.6

年份：2024

卷号：352

期号：　

开始页：60

结束页：66

文献类型：Article

关键词：Hemodialysis; Depression; Sertraline; Efficacy; Safety

摘要："Objective: To determine the efficacy and safety of sertraline in maintenance hemodialysis (MHD) patients with depression. Methods: A randomized controlled trial was conducted involving 125 MHD patients with depression. The treatment group received sertraline, while the control group did not receive any antidepressant treatment. After 12 weeks, we compared the changes in the Hamilton Depression Rating Scale (HAMD), the Medication Adherence Report Scale-5 (MARS-5), the Mini Nutritional Assessment short-form (MNA-SF), the Kidney Disease Quality of Life-36 (KDQOL-36) scores, selected clinical and laboratory indicators, and the incidence of drugrelated adverse reactions between the two groups. Results: After 12 weeks of treatment, the HAMD scores of patients in the treatment group significantly decreased compared to before treatment and were lower than those in the control group. The KDQOL-36, MARS-5, and MNA-SF scores in the treatment group also significantly improved compared to before treatment and were superior to those in the control group. Albumin and hemoglobin levels in the treatment group significantly increased, while C-reactive protein significantly decreased. The incidence of nausea was slightly higher in the treatment group, and was mostly relieved after reducing the dosage of sertraline. Limitations: This study is a single-center, small-sample study with a relatively short duration of treatment and follow-up. Conclusions: Sertraline can alleviate depressive symptoms, and improve the quality of life and treatment compliance of MHD patients, while improving chronic inflammation, malnutrition, and anemia. However, starting with a low dose and reducing the maintenance dose is recommended when administering sertraline."

基金机构：　

基金资助正文：